| scholarly article | Q13442814 |
| consensus development conference proceedings | Q58900768 |
| P2093 | author name string | A. Goldhirsch | |
| A. S. Coates | |||
| B. Thürlimann | |||
| E. P. Winer | |||
| H.-J. Senn | |||
| M. Gnant | |||
| M. Piccart-Gebhart | |||
| R. D. Gelber | |||
| P2860 | cites work | Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study | Q84018508 |
| Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapy | Q85722004 | ||
| Hypofractionated radiotherapy in early breast cancer: Clinical, dosimetric and radio-genomic issues | Q85847272 | ||
| Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints | Q85860184 | ||
| Comprehensive molecular portraits of human breast tumours | Q24630844 | ||
| Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer | Q27852282 | ||
| The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study | Q27853110 | ||
| Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications | Q27860709 | ||
| Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors | Q28247372 | ||
| Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) | Q28291395 | ||
| Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial | Q28305038 | ||
| Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies | Q29617680 | ||
| Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients | Q29617771 | ||
| Atypical hyperplasia of the breast--risk assessment and management options | Q30301033 | ||
| Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998-2002. | Q30692732 | ||
| Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial | Q33415041 | ||
| Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40 | Q33416887 | ||
| Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens | Q33559365 | ||
| Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX | Q33739357 | ||
| An epigenomic approach to therapy for tamoxifen-resistant breast cancer | Q33859350 | ||
| Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes | Q33892778 | ||
| Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. | Q34172008 | ||
| Adjuvant exemestane with ovarian suppression in premenopausal breast cancer | Q34245992 | ||
| A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer | Q34268261 | ||
| Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. | Q34354769 | ||
| PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. | Q34433549 | ||
| Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011. | Q34436508 | ||
| Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study | Q34485373 | ||
| Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group | Q34611626 | ||
| Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial | Q34919537 | ||
| Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience | Q34996659 | ||
| Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer | Q35038093 | ||
| Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). | Q35073164 | ||
| Adjuvant ovarian suppression in premenopausal breast cancer | Q35124558 | ||
| Axillary dissection can be avoided in the majority of clinically node-negative patients undergoing breast-conserving therapy | Q35147064 | ||
| Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. | Q35230273 | ||
| Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer | Q35264283 | ||
| Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. | Q35511100 | ||
| Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105 | Q35671356 | ||
| Adjuvant trastuzumab in HER2-positive breast cancer | Q35710898 | ||
| Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. | Q47719898 | ||
| Long-term results of hypofractionated radiation therapy for breast cancer | Q48887913 | ||
| Increasing rates of contralateral prophylactic mastectomy - a trend made in USA? | Q50969644 | ||
| Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. | Q51022930 | ||
| PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. | Q52874022 | ||
| Reply to Ki67 in breast cancer: a useful prognostic marker! | Q52880209 | ||
| No clear effect of postoperative radiotherapy on survival of breast cancer patients with one to three positive nodes: a population-based study. | Q53558578 | ||
| Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). | Q54346018 | ||
| Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer | Q57128234 | ||
| Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study | Q57579895 | ||
| Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 | Q59616705 | ||
| Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12 | Q59616706 | ||
| Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer | Q79572358 | ||
| The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer | Q83760986 | ||
| Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials | Q35740423 | ||
| A bad tumor biomarker is as bad as a bad drug: The gap between genomics data and phenotype to predict response | Q35740695 | ||
| The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer | Q35812158 | ||
| Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. | Q36389193 | ||
| Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer | Q36494250 | ||
| Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients | Q36609527 | ||
| The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. | Q36615770 | ||
| Molecular characterization of basal-like and non-basal-like triple-negative breast cancer | Q36630430 | ||
| Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial | Q36680024 | ||
| ASCO's approach to a learning health care system in oncology. | Q36835940 | ||
| Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer | Q36889647 | ||
| Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures | Q36955113 | ||
| Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers | Q37122297 | ||
| Factors predicting late recurrence for estrogen receptor-positive breast cancer | Q37209554 | ||
| Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes | Q37269261 | ||
| PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer | Q37380424 | ||
| The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. | Q37385272 | ||
| An international Ki67 reproducibility study | Q37463125 | ||
| High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial | Q37671966 | ||
| Which threshold for ER positivity? a retrospective study based on 9639 patients | Q37723520 | ||
| Evolution of sites of recurrence after early breast cancer over the last 20 years: implications for patient care and future research | Q38107410 | ||
| Margins in breast conservation: a clinician's perspective and what the literature tells us. | Q38206486 | ||
| Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial | Q38487646 | ||
| Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes | Q38576669 | ||
| An international study to increase concordance in Ki67 scoring | Q39037175 | ||
| Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study | Q39089283 | ||
| Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial | Q39404724 | ||
| Pregnancy after breast cancer: Are young patients willing to participate in clinical studies? | Q41463672 | ||
| Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors | Q41649154 | ||
| Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer Study. | Q41698029 | ||
| Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? | Q42647694 | ||
| Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response | Q42677733 | ||
| CT-planned internal mammary node radiotherapy in the DBCG-IMN study: benefit versus potentially harmful effects | Q43753715 | ||
| High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer. | Q43897506 | ||
| Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial | Q43951696 | ||
| Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy | Q44758203 | ||
| Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study | Q45330030 | ||
| The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. | Q46425805 | ||
| Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence | Q46895515 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | intraductal carcinoma | Q337585 |
| lymphadenectomy | Q1809305 | ||
| breast ductal carcinoma | Q3658404 | ||
| quadrantectomy | Q7268333 | ||
| breast lobular carcinoma | Q18553580 | ||
| breast neoplasm | Q23929670 | ||
| antineoplastic combined chemotherapy protocols | Q66764603 | ||
| P304 | page(s) | 1533-46 | |
| P577 | publication date | 2015-08-01 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 | |
| P478 | volume | 26 |
| Q30315970 | 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts |
| Q90448069 | 21-Gene recurrence score influences the chemotherapy decision for patients with breast cancer of different luminal subtypes |
| Q58597281 | A DNA Methylation-Based Test for Breast Cancer Detection in Circulating Cell-Free DNA |
| Q36968921 | A Decision Aid for Women Considering Neoadjuvant Systemic Therapy for Operable Invasive Breast Cancer: Development and Protocol of a Phase II Evaluation Study (ANZ1301 DOMINO). |
| Q37526339 | A METHYLATION-TO-EXPRESSION FEATURE MODEL FOR GENERATING ACCURATE PROGNOSTIC RISK SCORES AND IDENTIFYING DISEASE TARGETS IN CLEAR CELL KIDNEY CANCER. |
| Q52692110 | A Metabolomic Approach to Predict Breast Cancer Behavior and Chemotherapy Response. |
| Q37220398 | A Nomogram for Predicting the Pathological Response of Axillary Lymph Node Metastasis in Breast Cancer Patients |
| Q64267406 | A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer |
| Q33843780 | A breast cancer gene signature for indolent disease |
| Q36277052 | A comparison of Ki-67 counting methods in luminal Breast Cancer: The Average Method vs. the Hot Spot Method |
| Q47764300 | A gonadotropin-releasing hormone agonist for the prevention of docetaxel-induced gonadal damage. |
| Q37723914 | A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2- early breast cancer. |
| Q55065689 | A nomogram to predict adjuvant chemotherapy recommendation in breast cancer patients with intermediate recurrence score. |
| Q92884820 | A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database study |
| Q92488475 | A simple immunohistochemical bio-profile incorporating Bcl2 curbs those cases of invasive breast carcinoma for which an Oncotype Dx characterization is needed |
| Q50089374 | A study of association of Oncotype DX recurrence score with DCE-MRI characteristics using multivariate machine learning models |
| Q36706854 | A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer |
| Q37688480 | ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines |
| Q98159038 | AGR3 promotes estrogen receptor-positive breast cancer cell proliferation in an estrogen-dependent manner |
| Q36198154 | ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer |
| Q90598919 | Absence of Nuclear p16 Is a Diagnostic and Independent Prognostic Biomarker in Squamous Cell Carcinoma of the Cervix |
| Q37130142 | Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. |
| Q49721138 | Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers |
| Q40263701 | Adherence to guidelines and breast cancer patients survival: a population-based cohort study analyzed with a causal inference approach. |
| Q39260461 | Adjuvant Endocrine Therapy in Breast Cancer: Evolving Paradigms in Premenopausal Women. |
| Q90292751 | Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study |
| Q36915190 | Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. |
| Q47369157 | Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study |
| Q37570641 | Adjuvant chemotherapy and HER-2-directed therapy for early-stage breast cancer in the elderly |
| Q89835814 | Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database |
| Q40872467 | Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial |
| Q91989234 | Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration |
| Q36976772 | Adjuvant endocrine therapy in premenopausal women with breast cancer |
| Q37175081 | Adjuvant ovarian function suppression and cognitive function in women with breast cancer. |
| Q39018742 | Adjuvant trastuzumab: a 10-year overview of its benefit. |
| Q33560459 | Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10). |
| Q47662579 | Advances in fertility preservation of female patients with hematological malignancies. |
| Q31153510 | Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset |
| Q93104469 | Aligning the Aligners: Comparison of RNA Sequencing Data Alignment and Gene Expression Quantification Tools for Clinical Breast Cancer Research |
| Q92142246 | Although c‑MYC contributes to tamoxifen resistance, it improves cisplatin sensitivity in ER‑positive breast cancer |
| Q59128489 | An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project |
| Q57106403 | An Update on Breast Cancer Multigene Prognostic Tests-Emergent Clinical Biomarkers |
| Q47588672 | An inter-observer Ki67 reproducibility study applying two different assessment methods: on behalf of the Danish Scientific Committee of Pathology, Danish breast cancer cooperative group (DBCG). |
| Q61810892 | Analysis of Treg cell population in patients with breast cancer with respect to progesterone receptor status |
| Q33915010 | Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration |
| Q41346691 | Androgen receptor expression identifies patient with favorable outcome in operable triple negative breast cancer |
| Q64895271 | Array comparative genomic hybridization analysis discloses chromosome copy number alterations as indicators of patient outcome in lymph node-negative breast cancer. |
| Q47138534 | Assessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer |
| Q42365795 | Assessment of Ki67 and uPA/PAI-1 expression in intermediate-risk early stage breast cancers |
| Q40089766 | Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses' Health Study. |
| Q36419109 | Association between HER2 status and response to neoadjuvant anthracycline followed by paclitaxel plus carboplatin chemotherapy without trastuzumab in breast cancer |
| Q59789826 | Association between sleep-disordered breathing and breast cancer aggressiveness |
| Q93128715 | Association of LncRNA MEG3 polymorphisms with efficacy of neoadjuvant chemotherapy in breast cancer |
| Q42492427 | Association of Notch pathway down-regulation with Triple Negative/Basal-like breast carcinomas and high tumor-infiltrating FOXP3+ Tregs. |
| Q97435116 | Association of Sperm-Associated Antigen 5 and Treatment Response in Patients With Estrogen Receptor-Positive Breast Cancer |
| Q99609984 | Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer |
| Q92814338 | Autophagy Inhibition Induces the Secretion of Macrophage Migration Inhibitory Factor (MIF) with Autocrine and Paracrine Effects on the Promotion of Malignancy in Breast Cancer |
| Q37687524 | Axillary and internal mammary sentinel lymph node biopsy in breast cancer after neoadjuvant chemotherapy |
| Q59789918 | BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer |
| Q90473892 | Behavior of metastatic breast cancer according to subtype |
| Q26781177 | Biological markers of invasive breast cancer |
| Q38893074 | Biology and Management of Patients With Triple-Negative Breast Cancer |
| Q55142706 | Biology, staging, and treatment of breast cancer during pregnancy: reassessing the evidences. |
| Q48353102 | Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology |
| Q46076943 | Bioscore: A Staging System for Breast Cancer Patients that Reflects the Prognostic Significance of Underlying Tumor Biology |
| Q28109681 | Body Mass Index with Tumor 18F-FDG Uptake Improves Risk Stratification in Patients with Breast Cancer |
| Q37629662 | Bone metastasis risk factors in breast cancer. |
| Q30315429 | Breast Cancer Is Our Global Responsibility |
| Q64964574 | Breast Cancer Subtypes Present a Differential Production of Reactive Oxygen Species (ROS) and Susceptibility to Antioxidant Treatment. |
| Q36051600 | Breast Cancer-Specific Mortality Pattern and Its Changing Feature According to Estrogen Receptor Status in Two Time Periods |
| Q57117791 | Breast cancer |
| Q58799692 | Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations |
| Q39348755 | Breast cancer electron intraoperative radiotherapy: assessment of preoperative selection factors from a retrospective analysis of 758 patients and review of literature |
| Q36340427 | Breast cancer in Iraq is associated with a unimodally distributed predominance of luminal type B over luminal type A surrogates from young to old age |
| Q37592883 | Breast cancer in neurofibromatosis type 1: overrepresentation of unfavourable prognostic factors. |
| Q50033721 | Breast cancer in young women: do BRCA1 or BRCA2 mutations matter? |
| Q64067663 | Breast cancer quantitative proteome and proteogenomic landscape |
| Q52641223 | Breast cancer survival, survival disparities, and guideline-based treatment. |
| Q45943221 | Breast cancer: The translation of big genomic data to cancer precision medicine. |
| Q36667861 | Breast segmentectomy with rotation mammoplasty as an oncoplastic approach to extensive ductal carcinoma in situ |
| Q28072766 | Bridging the gap between clinicians and systems biologists: from network biology to translational biomedical research |
| Q61447500 | CD1d- and PJA2-related immune microenvironment differs between invasive breast carcinomas with and without a micropapillary feature |
| Q42502215 | CD44 induces FOXP3 expression and is related with favorable outcome in breast carcinoma. |
| Q41808474 | CD74 and intratumoral immune response in breast cancer |
| Q38974995 | Can Clinically Node-Negative Breast Cancer Patients with Suspicious Axillary Lymph Nodes at Ultrasound But Negative Fine-Needle Aspiration Be Approached as Having Node-Negative Disease? |
| Q49648522 | Can Histological Grade and Mitotic Index Replace Ki67 to Determine Luminal Breast Cancer Subtypes? |
| Q47978876 | Can algorithmically assessed MRI features predict which patients with a preoperative diagnosis of ductal carcinoma in situ are upstaged to invasive breast cancer? |
| Q43106184 | Cancer and fertility preservation: international recommendations from an expert meeting |
| Q49271132 | Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E2 and down-regulating the Wnt pathway activity |
| Q37639271 | Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping |
| Q26774622 | Chemotherapy in Premenopausal Breast Cancer Patients |
| Q91596428 | Circulating non‑coding RNA‑biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer? |
| Q60949496 | Clinical Differences in Triple-Positive Operable Breast Cancer Subtypes in Korean Patients: An Analysis of Korean Breast Cancer Registry Data |
| Q41622885 | Clinical Impact of Sphingosine-1-Phosphate in Breast Cancer |
| Q91636470 | Clinical Interest of Combining Transcriptomic and Genomic Signatures in High-Grade Serous Ovarian Cancer |
| Q51733186 | Clinical and economic impact of the 21-gene recurrence score assay in adjuvant therapy decision making in patients with early-stage breast cancer: pooled analysis in 4 Basque Country university hospitals. |
| Q47196323 | Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients |
| Q91681237 | Clinical and transcriptional signatures of human CD204 reveal an applicable marker for the protumor phenotype of tumor-associated macrophages in breast cancer |
| Q55334991 | Clinical application and utility of genomic assays in early-stage breast cancer: key lessons learned to date. |
| Q41476022 | Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry |
| Q41481374 | Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry |
| Q90149717 | Clinical outcomes of an intraoperative surgical margin assessment using the fresh frozen section method in patients with invasive breast cancer undergoing breast-conserving surgery - a single center analysis |
| Q40284336 | Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer |
| Q36395223 | Clinically relevant morphological structures in breast cancer represent transcriptionally distinct tumor cell populations with varied degrees of epithelial-mesenchymal transition and CD44+CD24- stemness. |
| Q46301419 | Clinicopathologic and prognostic features of breast cancer in young women: a series from North of Morocco. |
| Q41907807 | Clinicopathologic study of invasive micropapillary carcinoma of the breast |
| Q92399941 | Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer |
| Q92389536 | Clinicopathological Features and Disease Outcome in Breast Cancer Patients with Hormonal Receptor Discordance between Core Needle Biopsy and Following Surgical Sample |
| Q36365067 | Clinicopathological and Molecular Study of Triple-Negative Breast Cancer in Algerian Patients |
| Q92357783 | Clinicopathological and epidemiological significance of breast cancer subtype reclassification based on p53 immunohistochemical expression |
| Q55009101 | Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer. |
| Q40436942 | Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study |
| Q90402474 | Color-coded perfluorocarbon nanodroplets for multiplexed ultrasound and Photoacoustic imaging |
| Q91013280 | Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer. |
| Q47118129 | Comparable Survival between Additional Radiotherapy and Local Surgery in Occult Breast Cancer after Axillary Lymph Node Dissection: A Population-based Analysis |
| Q92565395 | Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer |
| Q36279137 | Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer |
| Q30315367 | Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial |
| Q64228159 | Comparison of the 7th and 8th edition of American Joint Committee on Cancer (AJCC) staging systems for breast cancer patients: a Surveillance, Epidemiology and End Results (SEER) Analysis |
| Q49951544 | Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial |
| Q47095927 | Computer-aided evaluation of the correlation between MRI morphology and immunohistochemical biomarkers or molecular subtypes in breast cancer |
| Q54940119 | Conventional Pathology Versus Gene Signatures for Assessing Luminal A and B Type Breast Cancers: Results of a Prospective Cohort Study. |
| Q48270057 | Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer. |
| Q58597805 | Correlation of tumor uptake on breast-specific gamma imaging and fluorodeoxyglucose PET/CT with molecular subtypes of breast cancer |
| Q41823897 | Correlations Between Oncotype DX Recurrence Score and Classic Risk Factors in Early Breast Cancer: Results of A Prospective Multicenter Study in Turkey |
| Q33661400 | Correlations between Tumor to Background Ratio on Breast-Specific Gamma Imaging and Prognostic Factors in Breast Cancer |
| Q55332159 | Correlations of aldehyde dehydrogenase-1 (ALDH1) expression with traditional prognostic parameters and different molecular subtypes of breast carcinoma. |
| Q28079880 | Current Status of Long Non-Coding RNAs in Human Breast Cancer |
| Q39405358 | Current advances in endocrine therapy options for premenopausal women with hormone receptor positive breast cancer |
| Q26767039 | Current status of ultrasound-guided surgery in the treatment of breast cancer |
| Q62786261 | Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer |
| Q39042324 | Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity |
| Q28830105 | DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer |
| Q39190318 | Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1. |
| Q36536652 | Defining lymphocyte-predominant breast cancer by the proportion of lymphocyte-rich stroma and its significance in routine histopathological diagnosis |
| Q58698569 | Differential effect of parity on rat mammary carcinogenesis after pre- or post-pubertal exposure to radiation |
| Q90463365 | Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study |
| Q93081609 | Differentially Expressed Mitochondrial Proteins in Human MCF7 Breast Cancer Cells Resistant to Paclitaxel |
| Q45943609 | Digital image analysis in breast pathology-from image processing techniques to artificial intelligence. |
| Q39967968 | Digital image analysis outperforms manual biomarker assessment in breast cancer. |
| Q30490708 | Discordance Rate in Estrogen Receptor, Progesterone Receptor, HER2 Status, and Ki67 Index Between Primary Unifocal and Multiple Homogenous Breast Carcinomas and Synchronous Axillary Lymph Node Metastases Have an Impact on Therapeutic Decision |
| Q47612310 | Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer |
| Q98564451 | Discordance in 21-gene recurrence scores between paired breast cancer samples is inversely associated with patient age |
| Q47870184 | Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study. |
| Q38629753 | Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China |
| Q36988793 | Does Breast Magnetic Resonance Imaging Combined With Conventional Imaging Modalities Decrease the Rates of Surgical Margin Involvement and Reoperation?: A Case-Control Comparative Analysis |
| Q33862200 | Does adjuvant chemotherapy change bone mineral density and related serum biomarkers in women with breast cancer? |
| Q41472829 | Does the 1H-NMR plasma metabolome reflect the host-tumor interactions in human breast cancer? |
| Q36379148 | Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts |
| Q41206460 | E-cadherin expression phenotypes associated with molecular subtypes in invasive non-lobular breast cancer: evidence from a retrospective study and meta-analysis |
| Q42373183 | ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy |
| Q93010229 | Early metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response |
| Q26782584 | Early-Stage Breast Cancer in the Elderly: Confronting an Old Clinical Problem |
| Q88933702 | Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial |
| Q50108898 | Effect of denosumab administration on low bone mineral density (T-score -1.0 to -2.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer |
| Q55001709 | Effect of miR-146a-5p on proliferation and metastasis of triple-negative breast cancer via regulation of SOX5. |
| Q57784764 | Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients |
| Q39683758 | Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. |
| Q48190639 | Efficacy of a global supportive skin care programme with hydrotherapy after non-metastatic breast cancer treatment: A randomised, controlled study |
| Q37706359 | Elevated YKL-40 expression is associated with a poor prognosis in breast cancer patients |
| Q38661390 | Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib. |
| Q43958170 | Endocrine prevention of chemotherapy-induced ovarian failure |
| Q47097891 | Endocrine sensitivity of estrogen receptor-positive breast cancer is negatively correlated with aspartate-β-hydroxylase expression |
| Q38658655 | Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence |
| Q92332465 | Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence |
| Q38674317 | Entinostat for the treatment of breast cancer. |
| Q34519347 | Equivalence of MammaPrint array types in clinical trials and diagnostics |
| Q33843822 | Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors |
| Q36941307 | Evaluating the Survival Benefit Following Ovarian Function Suppression in Premenopausal Patients with Hormone Receptor Positive Early Breast Cancer |
| Q47117712 | Evaluation of guidelines regarding surgical treatment of breast cancer using the AGREE Instrument: a systematic review |
| Q37536901 | Evaluation of the prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers |
| Q64065538 | Exploiting heat shock protein expression to develop a non-invasive diagnostic tool for breast cancer |
| Q64277845 | Exploring Collagen Parameters in Pure Special Types of Invasive Breast Cancer |
| Q90929458 | Exploring specific prognostic biomarkers in triple-negative breast cancer |
| Q42517474 | Expression and function of the miR-143/145 cluster in vitro and in vivo in human breast cancer. |
| Q58572347 | Expression of miRNA-206 and miRNA-145 in breast cancer and correlation with prognosis |
| Q48362604 | Expression of oxysterol pathway genes in oestrogen-positive breast carcinomas |
| Q33751079 | Expression of regulatory factor X1 can predict the prognosis of breast cancer |
| Q57795219 | Expression of survivin does not appear to influence breast cancer recurrence risk |
| Q36281258 | Extra-nodal extension is a significant prognostic factor in lymph node positive breast cancer |
| Q92859383 | Extracting Pathway-level Signatures from Proteogenomic Data in Breast Cancer Using Independent Component Analysis |
| Q51168093 | FGD5 amplification in breast cancer patients is associated with tumour proliferation and a poorer prognosis. |
| Q27853294 | FGFR1 is an adverse outcome indicator for luminal A breast cancers |
| Q55517966 | FOXA1 and AR in invasive breast cancer: new findings on their co-expression and impact on prognosis in ER-positive patients. |
| Q36746291 | FOXA1 expression affects the proliferation activity of luminal breast cancer stem cell populations |
| Q33872907 | FOXP3 Allelic Variants and Haplotype Structures Are Associated with Aggressive Breast Cancer Subtypes |
| Q38963455 | Factors associated with ovarian function recovery after chemotherapy for breast cancer: a systematic review and meta-analysis. |
| Q64882055 | Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer. |
| Q53099965 | Feasibility of Preoperative Axillary Lymph Node Marking with a Clip in Breast Cancer Patients Before Neoadjuvant Chemotherapy: A Preliminary Study. |
| Q93134519 | Fertility Preservation Using GnRH Agonists: Rationale, Possible Mechanisms, and Explanation of Controversy |
| Q33628044 | Fewer Reoperations After Lumpectomy for Breast Cancer with Neoadjuvant Rather than Adjuvant Chemotherapy: A Report from the National Cancer Database |
| Q58111463 | Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230 |
| Q47604446 | First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer |
| Q50948753 | Gemcitabine and Vinorelbine Combination Chemotherapy in Taxane-Pretreated Patients with Metastatic Breast Cancer: A Phase II Study of the Kinki Multidisciplinary Breast Oncology Group (KMBOG) 1015. |
| Q57116157 | Gene Expression Profiling in Breast Cancer and Its Effect on Therapy Selection in Early-Stage Breast Cancer |
| Q45069112 | Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts |
| Q57117421 | Genomic Testing in the Management of Early-Stage Breast Cancer |
| Q88693944 | Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab |
| Q58111459 | Gonadotropin-Releasing Hormone (GnRH) Agonists for Fertility Preservation: Is POEMS the Final Verse? |
| Q36478738 | Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy May Increase Pregnancy Rate in Survivors |
| Q64947702 | Gonadotropin-releasing hormone agonists during chemotherapy for ovarian function and fertility preservation for patients with early-stage breast cancer. |
| Q53097641 | Gonadotropin-releasing hormone analogs for ovarian function protection during chemotherapy in young early breast cancer patients: the last piece of the puzzle? |
| Q40714642 | HER2 gene copy number and breast cancer-specific survival |
| Q36087126 | HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy |
| Q53203084 | Head-to-head comparison of the impact of Aurora A, Aurora B, Repp86, CDK1, CDK2 and Ki67 expression in two of the most relevant gynaecological tumor entities. |
| Q47113036 | Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer |
| Q37676005 | High Residual Tumor Rate for Early Breast Cancer Patients Receiving Vacuum-assisted Breast Biopsy |
| Q57809318 | Higher Ki67 expression in fibroblast like cells at invasive front indicates better clinical outcomes in oral squamous cell carcinoma patients |
| Q64264397 | Higher axillary lymph node metastasis burden in breast cancer patients with positive preoperative node biopsy: may not be appropriate to receive sentinel lymph node biopsy in the post-ACOSOG Z0011 trial era |
| Q28077637 | Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women |
| Q39008777 | Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study. |
| Q92064459 | Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands |
| Q90781848 | Hsa-miR-210-3p expression in breast cancer and its putative association with worse outcome in patients treated with Docetaxel |
| Q64061927 | Identification and clinical validation of a multigene assay that interrogates the biology of cancer stem cells and predicts metastasis in breast cancer: A retrospective consecutive study |
| Q99635780 | Identification and validation of stemness-related lncRNA prognostic signature for breast cancer |
| Q57116871 | Identifying Biomarkers to Select Patients with Early Breast Cancer Suitable for Extended Adjuvant Endocrine Therapy |
| Q33763563 | Imaging Surveillance After Primary Breast Cancer Treatment |
| Q42515438 | Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial. |
| Q36791866 | Impact of Oncotype DX Recurrence Score on Treatment Decisions: Results of a Prospective Multicenter Study in Turkey. |
| Q39557649 | Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy. |
| Q61809710 | Impact of clinical and pathological factors on local recurrence after breast-conserving treatment: CT-based localization for a tumor bed boost yielded better local control when compared with a surgical scar |
| Q55208892 | Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial. |
| Q58799791 | Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer |
| Q91894593 | Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy |
| Q35717509 | Improved adjuvant endocrine therapy for premenopausal women with endocrine responsive disease |
| Q61453026 | Improved prognosis of low baseline neutrophil-to-lymphocyte ratio is significantly exclusive in breast cancer patients with high absolute counts of lymphocytes |
| Q91796697 | In-cell determination of Lactate Dehydrogenase Activity in a Luminal Breast Cancer Model ⁻ ex vivo Investigation of Excised Xenograft Tumor Slices Using dDNP Hyperpolarized [1-13C]pyruvate |
| Q49718375 | Incorporating Risk Factors to Identify the Indication of Post-mastectomy Radiotherapy in N1 Breast Cancer Treated with Optimal Systemic Therapy: A Multicenter Analysis in Korea (KROG 14-23). |
| Q45134639 | Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System |
| Q38772800 | Influence of comorbidity on chemotherapy use for early breast cancer: systematic review and meta-analysis. |
| Q41234329 | Influence of delayed initiation of adjuvant chemotherapy on breast cancer survival is subtype-dependent |
| Q90577015 | Inhibition of the PI3K-AKT-mTOR pathway suppresses the adipocyte-mediated proliferation and migration of breast cancer cells |
| Q47253554 | Instrumented Spinal Stabilization without Fusion for Spinal Metastatic Disease |
| Q48190129 | Integrating anatomy, radiology, pathology, and surgery: An alternative approach in resecting multifocal and multicentric breast carcinoma. |
| Q57178370 | Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5 |
| Q91526464 | Integration of Ki-67 index into AJCC 2018 staging provides additional prognostic information in breast tumours candidate for genomic profiling |
| Q51716428 | Intratumoral heterogeneity of Ki67 expression in early breast cancers exceeds variability between individual tumours. |
| Q60931821 | Introduction of a New Staging System of Breast Cancer for Radiologists: An Emphasis on the Prognostic Stage |
| Q38597055 | Inverse relationship between Ki67 and survival in early luminal breast cancer: confirmation in a multivariate analysis. |
| Q38691029 | Investigational and experimental GnRH analogs and associated neurotransmitters |
| Q93378075 | Is Axillary Sentinel Lymph Node Biopsy Required in Patients Who Undergo Primary Breast Surgery? |
| Q53101382 | Is there an Ideal Breast Conservation Rate for the Treatment of Breast Cancer? |
| Q39091739 | Jim Crow and estrogen-receptor-negative breast cancer: US-born black and white non-Hispanic women, 1992-2012. |
| Q58698990 | Ki 67 assessment in breast cancer in an Egyptian population: a comparative study between manual assessment on optical microscopy and digital quantitative assessment |
| Q47160829 | Ki-67 Expression by Immunohistochemistry and Quantitative Real-Time Polymerase Chain Reaction as Predictor of Clinical Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. |
| Q92898526 | Ki-67 Expression is a Significant Prognostic Factor Only When Progesterone Receptor Expression is Low in Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer |
| Q37596690 | Ki-67 as a prognostic marker according to breast cancer molecular subtype |
| Q90183177 | Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort |
| Q90836127 | Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study |
| Q52680900 | Ki67 Changes Identify Worse Outcomes in Residual Breast Cancer Tumors After Neoadjuvant Chemotherapy. |
| Q55340786 | Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer. |
| Q33843751 | Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections |
| Q36530491 | Ki67--An unsuitable marker of gastric cancer prognosis unmasks intratumoral heterogeneity |
| Q33591751 | Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer |
| Q55438036 | Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer. |
| Q58550839 | Low PR in ER(+)/HER2(-) breast cancer: high rates of TP53 mutation and high SUV |
| Q93013658 | Low total pathologic complete response rate to preoperative chemotherapy in patients with invasive lobular carcinomaof the breast |
| Q36057458 | Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. |
| Q49948404 | Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis |
| Q89396965 | Lymph Node Status in Breast Cancer Does Not Predict Tumor Biology |
| Q38813226 | Lymph Node Surgery - Stepwise Retirement for the Breast Surgeon? |
| Q33843799 | MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer. |
| Q89948271 | MRI Radiomic Features: Association with Disease-Free Survival in Patients with Triple-Negative Breast Cancer |
| Q41545259 | MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer. |
| Q55396722 | Management of the Axilla in the Era of Breast Cancer Heterogeneity. |
| Q47584016 | Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer |
| Q35962498 | Meta-analysis of the concordance of histological grade of breast cancer between core needle biopsy and surgical excision specimen |
| Q49871101 | Metabolic Footprints and Molecular Subtypes in Breast Cancer |
| Q55084135 | Methylation-to-Expression Feature Models of Breast Cancer Accurately Predict Overall Survival, Distant-Recurrence Free Survival, and Pathologic Complete Response in Multiple Cohorts. |
| Q39510045 | Metrics for monitoring cancer inequities: residential segregation, the Index of Concentration at the Extremes (ICE), and breast cancer estrogen receptor status (USA, 1992-2012). |
| Q37746031 | MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24. |
| Q41169679 | MicroRNA-519a-3p mediates apoptosis resistance in breast cancer cells and their escape from recognition by natural killer cells |
| Q48229387 | Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative. |
| Q26751172 | Molecular Testing and the Pathologist's Role in Clinical Trials of Breast Cancer |
| Q33750808 | Molecular characterization of breast cancer cell lines by clinical immunohistochemical markers. |
| Q91519389 | Molecular pathogenesis of triple-negative breast cancer based on microRNA expression signatures: antitumor miR-204-5p targets AP1S3 |
| Q28069885 | Molecular subtypes and imaging phenotypes of breast cancer. |
| Q47374603 | Molecular subtyping of breast cancer improves identification of both high and low risk patients. |
| Q98217858 | Multiparametric MRI-based radiomics analysis for the prediction of breast tumor regression patterns after neoadjuvant chemotherapy |
| Q37388175 | Muscle Biopsy Findings in Combination With Myositis-Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis |
| Q92701866 | N-Cadherin mRNA Levels in Peripheral Blood Could Be a Potential Indicator of New Metastases in Breast Cancer: A Pilot Study |
| Q39375196 | Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. |
| Q89285491 | Neoadjuvant chemoradiation and breast reconstruction: the potential for improved outcomes in the treatment of breast cancer |
| Q89924122 | Neoadjuvant chemotherapy-induced decrease of prognostic nutrition index predicts poor prognosis in patients with breast cancer |
| Q87275262 | Neoadjuvant nab-paclitaxel in breast cancer: trial results and patient care |
| Q45073151 | Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial |
| Q38870541 | News on the medical treatment of young women with early-stage HER2-negative breast cancer |
| Q49221038 | No Association of Positive Superficial and/or Deep Margins with Local Recurrence in Invasive Breast Cancer Treated with Breast-Conserving Surgery |
| Q31160308 | Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer pa |
| Q59790149 | Non-linear transformations of age at diagnosis, tumor size, and number of positive lymph nodes in prediction of clinical outcome in breast cancer |
| Q41091405 | Nuclear PARP1 expression and its prognostic significance in breast cancer patients. |
| Q55285404 | Obesity as risk factor for subtypes of breast cancer: results from a prospective cohort study. |
| Q88630599 | Omitting Adjuvant Radiotherapy for Hormone Receptor‒Positive Early-Stage Breast Cancer in Old Age: A Propensity Score Matched SEER Analysis |
| Q40932624 | Oncoplastic Breast-Conserving Surgery for Tumors Larger than 2 Centimeters: Is it Oncologically Safe? A Matched-Cohort Analysis. |
| Q36922535 | Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up |
| Q37702175 | Optimal radiation dose for patients with one to three lymph node positive breast cancer following breast-conserving surgery and anthracycline plus taxane-based chemotherapy: A retrospective multicenter analysis (KROG 1418). |
| Q87609527 | Optimising Breast Conservation Treatment for Multifocal and Multicentric Breast Cancer: A Worthwhile Endeavour?: Reply |
| Q38968531 | Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer. |
| Q38992134 | Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer |
| Q35766397 | Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. |
| Q55176796 | Overexpression of topoisomerase II alpha protein is a factor for poor prognosis in patients with luminal B breast cancer. |
| Q59329631 | Overview of the pathological results and treatment characteristics in the first 1000 patients randomized in the SERC trial: axillary dissection versus no axillary dissection in patients with involved sentinel node |
| Q57160039 | PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma |
| Q64897531 | PROGNOSTIC IMPACT OF LOW ESTROGEN AND PROGESTERONE POSITIVITY IN LUMINAL B (HER2 NEGATIVE) BREAST CANCER. |
| Q93060888 | Paradigm Shift From Halstedian Radical Mastectomy to Personalized Medicine |
| Q90645887 | Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel |
| Q44981222 | Pathway Oriented Therapy in Breast Cancer - a Light at the End of the Tunnel! |
| Q58777248 | Pathway-Based Drug Repositioning for Breast Cancer Molecular Subtypes |
| Q42690907 | Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online. |
| Q39232374 | Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer |
| Q64950122 | Phospho‑STAT1 expression as a potential biomarker for anti‑PD‑1/anti‑PD‑L1 immunotherapy for breast cancer. |
| Q50951782 | Postmenopausal breast cancer: a best endocrine strategy? |
| Q59812268 | Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis |
| Q33717341 | Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index |
| Q48103965 | Pre-operative and intra-operative detection of axillary lymph node metastases in 108 patients with invasive lobular breast cancer undergoing mastectomy |
| Q55379220 | Precision Medicine in Hormone Receptor-Positive Breast Cancer. |
| Q33809114 | Precision medicine in breast cancer: reality or utopia? |
| Q45339854 | Predicting level 2 axillary lymph node metastasis in a Chinese breast cancer population post-neoadjuvant chemotherapy: development and assessment of a new predictive nomogram |
| Q57816466 | Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers |
| Q41545839 | Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy |
| Q98386288 | Predictive and prognostic value of EPIC1 in patients with breast cancer receiving neoadjuvant chemotherapy |
| Q89455386 | Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials |
| Q88008751 | Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer |
| Q48136997 | Predictive value of vascular endothelial growth factor receptor type 2 in triple-negative breast cancer patients treated with neoadjuvant chemotherapy. |
| Q38709809 | Preexposure of MCF-7 breast cancer cell line to dexamethasone alters the cytotoxic effect of paclitaxel but not 5-fluorouracil or epirubicin chemotherapy |
| Q49716199 | Preliminary Study of the Role F-Box Protein 32 (FBXO32) in Colorectal Neoplasms Through the Transforming Growth Factor beta (TGF-β)/Smad4 Signalling Pathway. |
| Q30316383 | Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015). |
| Q48365386 | Primary tumor location predicts the site of local relapse after nipple-areola complex (NAC) sparing mastectomy. |
| Q36729240 | Progesterone receptor loss identifies hormone receptor-positive and HER2-negative breast cancer subgroups at higher risk of relapse: a retrospective cohort study |
| Q36135274 | Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study |
| Q54495437 | Prognostic & predictive factors for planning adjuvant chemotherapy of early-stage breast cancer. |
| Q89471843 | Prognostic DNA methylation markers for hormone receptor breast cancer: a systematic review |
| Q50281398 | Prognostic Impact of Elective Supraclavicular Nodal Irradiation for Patients with N1 Breast Cancer after Lumpectomy and Anthracycline Plus Taxane-Based Chemotherapy (KROG 1418): A Multicenter Case-Controlled Study |
| Q37735963 | Prognostic Influence of BCL2 on Molecular Subtypes of Breast Cancer |
| Q36030084 | Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis |
| Q37075648 | Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies |
| Q42001306 | Prognostic immune-related gene models for breast cancer: a pooled analysis |
| Q38690101 | Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2- pN0 early breast cancers. |
| Q52880311 | Prognostic implications of securin expression and sub-cellular localization in human breast cancer. |
| Q36243382 | Prognostic significance of Ki67 in Chinese women diagnosed with ER+/HER2- breast cancers by the 2015 St. Gallen consensus classification |
| Q47122813 | Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up |
| Q27853207 | Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients |
| Q41421740 | Prognostic value of routine laboratory variables in prediction of breast cancer recurrence |
| Q26798078 | Progress in adjuvant chemotherapy for breast cancer: an overview |
| Q48163403 | Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada. |
| Q42517033 | Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers |
| Q59812270 | Protein expression profile and microRNA expression signature in estrogen receptor-positive and -negative breast cancers: report of two cases |
| Q48154363 | Quality assurance trials for Ki67 assessment in pathology |
| Q64112956 | Quantification of intrinsic subtype ambiguity in Luminal A breast cancer and its relationship to clinical outcomes |
| Q90465807 | RASEF expression correlates with hormone receptor status in breast cancer |
| Q47577157 | Randomized trial of aromatherapy versus conventional care for breast cancer patients during perioperative periods. |
| Q64284818 | Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant |
| Q64947136 | Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material. |
| Q38903641 | Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes |
| Q38374747 | Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. |
| Q64887142 | Relationship between Tumor Infiltrating Lymphocytes and Progression in Breast Cancer. |
| Q45966794 | Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast. |
| Q48719284 | Reliability of the Ki67-Labelling Index in Core Needle Biopsies of Luminal Breast Cancers is Unaffected by Biopsy Volume |
| Q58465937 | Reply to the letter to the editor ‘Can ovarian suppression with gonadotropin releasing hormone analogs (GnRHa) preserve fertility in cancer patients?’ by Rodriguez-Wallberg et al |
| Q40460628 | Reproducibility and Prognostic Potential of Ki-67 Proliferation Index when Comparing Digital-Image Analysis with Standard Semi-Quantitative Evaluation in Breast Cancer. |
| Q49690574 | Response letter to: Questions about Ki67 staining in luminal breast cancer |
| Q37709879 | Restricted Axillary Staging in Clinically and Sonographically Node-Negative Early Invasive Breast Cancer (c/iT1-2) in the Context of Breast Conserving Therapy: First Results Following Commencement of the Intergroup-Sentinel-Mamma (INSEMA) Trial |
| Q50271137 | Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. |
| Q60309933 | Rho GTPase Activating Protein 24 (ARHGAP24) Regulates the Anti-Cancer Activity of Sorafenib Against Breast Cancer MDA-MB-231 Cells via the Signal Transducer and Activator of Transcription 3 (STAT3) Signaling Pathway |
| Q35949292 | Risk Factors Associated with Discordant Ki-67 Levels between Preoperative Biopsy and Postoperative Surgical Specimens in Breast Cancers |
| Q36310705 | Risk factors for delay of adjuvant chemotherapy in non-metastatic breast cancer patients: A systematic review and meta-analysis involving 186982 patients |
| Q90152448 | Robust and interpretable PAM50 reclassification exhibits survival advantage for myoepithelial and immune phenotypes |
| Q88991289 | Role of DCE-MR in predicting breast cancer subtypes |
| Q33553668 | Role of postmastectomy radiotherapy in early-stage (T1-2N0-1M0) triple-negative breast cancer: a systematic review |
| Q59804254 | RollFISH achieves robust quantification of single-molecule RNA biomarkers in paraffin-embedded tumor tissue samples |
| Q39677335 | SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis. |
| Q87684800 | SPAG5: the ultimate marker of proliferation in early breast cancer? |
| Q91804592 | Sentinel lymph node biopsy in microinvasive ductal carcinoma in situ |
| Q37265272 | Sentinel lymph nodes for breast carcinoma: an update on current practice |
| Q38599786 | Separase is a marker for prognosis and mitotic activity in breast cancer. |
| Q58758376 | Sepsis: Personalized Medicine Utilizing 'Omic' Technologies-A Paradigm Shift? |
| Q37453940 | Sequencing-based breast cancer diagnostics as an alternative to routine biomarkers |
| Q92864409 | Should a Multigene Signature be Used in all Luminal Early Breast Cancers |
| Q50052578 | Significance of lung biopsy for the definitive diagnosis of lung nodules in breast cancer patients |
| Q90179380 | Single Tumor Cells With Epithelial-Like Morphology Are Associated With Breast Cancer Metastasis |
| Q38881805 | Sorafenib for the treatment of breast cancer |
| Q37153297 | Sorafenib in breast cancer treatment: A systematic review and overview of clinical trials |
| Q54976962 | Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer. |
| Q48511251 | St Gallen 2015 subtyping of luminal breast cancers: impact of different Ki67-based proliferation assessment methods |
| Q49035702 | St Gallen International Expert Consensus on the primary therapy of early breast cancer: an invaluable tool for physicians and scientists |
| Q57489064 | Status of FAS and FAS Ligand Gene Polymorphisms in Patients with Breast Cancer in Northeastern IRAN |
| Q33572252 | Stemness in Cancer: Stem Cells, Cancer Stem Cells, and Their Microenvironment. |
| Q89847896 | Strategies to Improve Recruitment to a De-escalation Trial: A Mixed-Methods Study of the OPTIMA Prelim Trial in Early Breast Cancer |
| Q36715181 | Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer |
| Q55282718 | Survival benefit of neoadjuvant chemotherapy for resectable breast cancer: A meta-analysis. |
| Q57179206 | Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers |
| Q62583463 | TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating Lymphocytes |
| Q59794738 | Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial |
| Q88971883 | Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer |
| Q26768119 | Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives |
| Q89840285 | Targeting claudin-4 enhances chemosensitivity in breast cancer |
| Q58609599 | Targeting the Hippo Pathway for Breast Cancer Therapy |
| Q38747402 | The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis |
| Q92828854 | The Changing Role of Gene-Expression Profiling in the Era of De-escalating Adjuvant Chemotherapy in Early-Stage Breast Cancer |
| Q91879339 | The Correlation of Magee EquationsTM and Oncotype DX® Recurrence Score From Core Needle Biopsy Tissues in Predicting Response to Neoadjuvant Chemotherapy in ER+ and HER2- Breast Cancer |
| Q37488980 | The Efficacy of Intraoperative Frozen Section Analysis During Breast-Conserving Surgery for Patients with Ductal Carcinoma In Situ |
| Q91869190 | The Impact of Pathway Database Choice on Statistical Enrichment Analysis and Predictive Modeling |
| Q41052166 | The Impact of Young Age for Prognosis by Subtype in Women with Early Breast Cancer |
| Q36880048 | The Metabolism, Analysis, and Targeting of Steroid Hormones in Breast and Prostate Cancer |
| Q28085160 | The Modern Landscape of Endocrine Therapy for Premenopausal Women with Breast Cancer |
| Q33572096 | The Noninvasive Treatment for Sentinel Lymph Node Metastasis by Photodynamic Therapy Using Phospholipid Polymer as a Nanotransporter of Verteporfin |
| Q92509065 | The Role of Exosomal MicroRNAs in the Tumor Microenvironment of Breast Cancer |
| Q55509868 | The Roles of p53 in Mitochondrial Dynamics and Cancer Metabolism: The Pendulum between Survival and Death in Breast Cancer? |
| Q98503936 | The TP53 mutation rate differs in breast cancers that arise in women with high or low mammographic density |
| Q36653693 | The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. |
| Q40570290 | The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone |
| Q90259059 | The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status |
| Q50433076 | The laminin-derived peptide C16 regulates GPNMB expression and function in breast cancer. |
| Q28067745 | The neutrophil lymphocyte ratio is associated with breast cancer prognosis: an updated systematic review and meta-analysis |
| Q38771946 | The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis |
| Q91865257 | The prognosis comparison of different molecular subtypes of breast tumors after radiotherapy and the intrinsic reasons for their distinct radiosensitivity |
| Q39226891 | The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients. |
| Q37520235 | The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases. |
| Q46842412 | The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer |
| Q52627272 | The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer. |
| Q47111746 | The prognostic value of Ki67 in ovarian high-grade serous carcinoma: an 11-year cohort study of Chinese patients |
| Q47097677 | The role of BRCA status on prognosis in patients with triple-negative breast cancer |
| Q92784739 | The single-cell pathology landscape of breast cancer |
| Q26768201 | The use of postoperative radiation after nipple sparing mastectomy |
| Q47638243 | Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer. |
| Q35998675 | Toolbox to Reduce Lumpectomy Reoperations and Improve Cosmetic Outcome in Breast Cancer Patients: The American Society of Breast Surgeons Consensus Conference |
| Q91974174 | Towards personalized treatment for early stage HER2-positive breast cancer |
| Q26738691 | Towards tumor immunodiagnostics |
| Q34519034 | Translating RNA sequencing into clinical diagnostics: opportunities and challenges. |
| Q38973381 | Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany |
| Q48294650 | Trastuzumab without chemotherapy in the adjuvant treatment of breast cancer: subgroup results from a large observational study |
| Q37130218 | Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. |
| Q39356527 | Treatment with aromatase inhibitors and markers of cardiovascular disease. |
| Q47564468 | Triple negative breast cancer - prognostic role of immune-related factors: a systematic review. |
| Q37645090 | Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway. |
| Q57168433 | Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs |
| Q36940085 | Triple-negative breast cancer: treatment challenges and solutions |
| Q49608951 | Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer |
| Q52318759 | Tumor xenograft modeling identifies an association between TCF4 loss and breast cancer chemoresistance. |
| Q90341056 | Tumor-infiltrating lymphocytes and CD8+ T cells predict survival of triple-negative breast cancer |
| Q38734804 | Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility. |
| Q47988029 | Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer. |
| Q89638568 | UCH-L1-mediated Down-regulation of Estrogen Receptor α Contributes to Insensitivity to Endocrine Therapy for Breast Cancer |
| Q57787055 | UNBS5162 induces growth inhibition and apoptosis via inhibiting PI3K/AKT/mTOR pathway in triple negative breast cancer MDA-MB-231 cells |
| Q52587869 | Update on the Treatment of Early-Stage Triple-Negative Breast Cancer. |
| Q64374643 | Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy |
| Q46082799 | Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer |
| Q64325302 | Validation of Breast Cancer Models for Predicting the Nonsentinel Lymph Node Metastasis After a Positive Sentinel Lymph Node Biopsy in a Chinese Population |
| Q37101590 | Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin |
| Q97529437 | Variability in hospital treatment costs: a time-driven activity-based costing approach for early-stage invasive breast cancer patients |
| Q47158989 | Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: a prospective, single arm, phase II study |
| Q93378077 | What Is the Best Management of cN0pN1(sn) Breast Cancer Patients? |
| Q92401267 | Which of the fluorine-18 fluorodeoxyglucose positron emission tomography/computerized tomography parameters are better associated with prognostic factors in breast cancer? |
| Q91756511 | Young-onset breast cancer: a poor prognosis only exists in low-risk patients |
| Q89488565 | [Chemotherapy and young women in breast cancer: what management?] |
| Q64907516 | hERG1 channel expression associates with molecular subtypes and prognosis in breast cancer. |
Search more.